
1. protein expr purif. 2017 aug;136:52-57. doi: 10.1016/j.pep.2015.06.011. epub 2015
nov 11.

production recombinant pvdbpii, receptor binding domain plasmodium vivax
duffy binding protein, evaluation immunogenicity identify adjuvant
formulation vaccine development.

bhardwaj r(1), shakri ar(1), hans d(1), gupta p(1), fernandez-becerra c(2), del
portillo ha(3), pandey g(4), chitnis ce(5).

author information: 
(1)international centre genetic engineering biotechnology (icgeb), new
delhi, india.
(2)barcelona centre international health (cresib), barcelona, spain.
(3)barcelona centre international health (cresib), barcelona, spain;
institució catalana de recerca estudis avançats (icrea), barcelona, spain.
(4)malaria vaccine development program (mvdp), new delhi, india.
(5)international centre genetic engineering biotechnology (icgeb), new
delhi, india. electronic address: chetan.chitnis@pasteur.fr.

plasmodium vivax dependent interaction duffy antigen receptor 
chemokines (darc) invasion human erythrocytes. p. vivax duffy binding 
protein (pvdbp) mediates interaction p. vivax merozoites darc. darc
receptor-binding domain lies conserved n-terminal cysteine-rich region of
pvdbp referred region ii (pvdbpii). pvdbpii attractive vaccine
candidate since antibodies raised pvdbpii block erythrocyte invasion by
p. vivax. here, describe methods produce recombinant pvdbpii its
correctly folded conformation. synthetic gene optimized expression of
pvdbpii escherichia coli fed batch fermentation process based on
exponential feeding strategy used achieve high levels expression of
recombinant pvdbpii. recombinant pvdbpii isolated inclusion bodies,
refolded rapid dilution purified ion exchange chromatography. purified 
recombinant pvdbpii characterized identity, purity functional
activity using standardized release assays. recombinant pvdbpii formulated with
various human compatible adjuvants including glycosylpyranosyl lipid a-stable
emulsion (gla-se) alhydrogel used immunogenicity studies small
animals downselect suitable formulation clinical development. sera
collected immunized animals tested recognition pvdbpii and
inhibition pvdbpii-darc binding. gla-se formulations pvdbpii yielded higher
elisa binding inhibition titres compared pvdbpii formulated with
alhydrogel. data support development recombinant vaccine for
p. vivax based pvdbpii formulated gla-se.

copyright © 2017 elsevier inc. rights reserved.

doi: 10.1016/j.pep.2015.06.011 
pmid: 26578115  [indexed medline]

